Recent Press Releases
January 08, 2026
NervGen announced the Company's common shares have been approved for listing on Nasdaq. NervGen’s common shares will begin trading on Nasdaq today, under the symbol “NGEN.”
December 17, 2025
NervGen announced it has filed a registration statement on Form F-10 with the United States Securities and Exchange Commission in accordance with the Multijurisdictional Disclosure System established between Canada and the United States.
November 24, 2025
NervGen announced expanded CONNECT SCI Study data demonstrating unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic SCI.
Phase 1b/2a CONNECT SCI Study for
Individuals with Spinal Cord Injury
For information regarding recruitment, the call center phone number is +1 (855) 559-6902.
Stay Connected
Subscribe to our mailing list to stay up to date
